Checkpoint Therapeutics has announced new pharmacokinetic data on cosibelimab, supporting the extension to an every-three-week dosing regimen. The data was presented at the Population Approach Group Europe 2023 annual meeting. The data supports the proposed 1200 mg every-three-week commercial dosing regimen for cosibelimab included in the Biologics License Application for advanced cutaneous squamous cell carcinoma currently under review by the FDA. The company believes cosibelimab has the potential to capture significant market share in the $1.6 billion U.S. market for cutaneous squamous cell carcinoma treatment.